K.C. Pharmaceuticals Eye Drop Recall – Case Investigation

The Block Firm is beginning to investigate the K.C. Pharmaceuticals eye drop recall and potential claims for those who have been affected. The FDA has issued a warning letter to K.C. Pharmaceuticals, Inc., a Pomona, California manufacturer of sterile eye drop products, citing serious, ongoing failures in the way the company makes its products.

On August 12, 2026, the FDA sent K.C. Pharmaceuticals a warning letter following an inspection of its facility earlier this year. The letter details a pattern of manufacturing failures that call into question whether the company’s eye drops are reliably sterile.

What the FDA Found

The warning letter lays out a list of violations, including:

• Repeated failures in the company’s sterility testing process going back to 2024.
• Unsafe practices inside the sterile manufacturing area, including workers breaching sterile barriers and using improper technique during the filling process.
• Inadequate inspection procedures that were not designed to catch particles or foreign material in the finished eye drop bottles.
• Insufficient stability testing to confirm the products remained safe and effective over their shelf life.
• A weak complaint-handling process that delayed investigation of safety issues raised by customers.

The FDA also noted that K.C. Pharmaceuticals received a similar warning letter back in 2023 — meaning the company had already been put on notice about serious sterility problems and failed to fix them.

Why This Matters for Patients

When a manufacturer can’t assure sterility during the filling process, contaminated product can reach consumers’ medicine cabinets — and their eyes. Eye infections tied to non-sterile eye drops can range from irritation to serious, vision-threatening infections.

The Recall

In March 2026, K.C. Pharmaceuticals recalled multiple lines of over-the-counter eye drops due to “lack of assurance of sterility” tied to its aseptic filling process between March 27, 2024, and November 7, 2024. K.C. Pharmaceuticals has since committed to suspending production at the facility altogether while it addresses the FDA’s findings.

Because K.C. Pharmaceuticals is the manufacturer and not distributor of these eye drops, these drops are sold under dozens of store and private labels names that are listed below.

Brands and products that may be affected include:

• Geri-Care (Artificial Tears, Dry Eye Relief)
• Walgreens Eye Drops
• CVS Eye Drops
• Kroger Eye Drops
• Harris Teeter Eye Drops
• Meijer Eye Drops
• Discount Drug Mart Eye Drops A.C.
• Best Choice Eye Drops
• QC-Quality Choice Eye Drops
• Good Sense Eye Drops
• CareOne Eye Drops
• Equaline Eye Drops
• TopCare / TopCare Health Eye Drops
• Leader Eye Drops
• Good Neighbor Pharmacy Eye Drops
• Rugby Lubricating Eye Drops
• Industrial Eye Relief

Product types covered by the recall include Artificial Tears, Eye Drops A.C., Advanced Relief, Dry Eye Relief, Ultra Lubricating Eye Drops, Original Formula, Redness Lubricant, and Soothing Tears — all in 0.5 oz (15 mL) bottles.

How This Connects to Our Investigation

The Block Firm is investigating claims on behalf of consumers who have been affected by this K.C. Pharmaceuticals eye drop recall. Consumers who paid for eye drops that were never reliably sterile — let alone those who experienced eye irritation or infection after use — may be entitled to compensation.

We’ll continue monitoring this situation as it develops. If you or a loved one used a recalled K.C. Pharmaceuticals-manufactured eye drop product, contact us today to learn more.